EPCORE FL-1: A phase 3 trial of epcoritamab with rituximab and lenalidomide in people with relapsed or refractory follicular lymphoma

This trial aims to see how safe and effective epcoritamab is when given with lenalidomide and rituximab in people with follicular lymphoma (FL) that has returned after (relapsed) or not responded (refractory) to treatment.

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT05409066

Trial aim and background

The aim of this trial is to see how safe, well tolerated and effective the treatment epcoritamab is when given in combination with rituximab and lenalidomide for people with relapsed or refractory FL.

People in the trial will receive rituximab and lenalidomide alone, or in combination with epcoritamab.

Epcoritamab is a type of bispecific antibody which sticks to one protein on the lymphoma cell, and one on healthy T cells (immune cells that kill other cells).

Who can enter 

Adults with grade 1 to 3a follicular lymphoma which has relapsed or is refractory to treatment may be eligible for this trial.

Locations 

Recruitment is taking place at the following UK locations:

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham
  • East Suffolk and North Essex NHS Foundation Trust, Colchester
  • Leeds Teaching Hospitals NHS Trust, Leeds
  • Clatterbridge Cancer Centre, Liverpool
  • The Christie Hospital, Manchester
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle
  • Portsmouth Hospitals University NHS Trust, Portsmouth
  • Derriford Hospitals and the Royal Eye Infirmary, Plymouth
  • Barts Health NHS Trust, London
  • Oxford University Hospitals NHS Foundation Trust, Oxford
  • NHS Greater Glasgow and Clyde, Glasgow

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05409066

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.